Acorai has completed patient enrollment for its CAPTURE-HF study, involving over 1,600 participants from 20 hospitals in six countries. This positions them well for future regulatory submissions.
Acorai CEO, Filip Peters, states that this new funding will enable the company to scale up clinical and regulatory efforts to bring its innovative cardiac care solutions to market.
With an FDA Breakthrough Device Designation, Acorai is on track for commercial launch by 2026, marking a significant milestone for heart failure management technologies.
Peters emphasizes that this investment is crucial for the clinical validation and early commercialization of their non-invasive cardiac care device, aiming to impact over 60 million worldwide.
Collection
[
|
...
]